Chugai Pharmaceuticals Co., Ltd. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 2/1/2026)
| Balance Sheet | Total Assets | 2,468,600,000,000.00 | ROE | 82.06 % |
| Balance Sheet | Total Equity | 2,025,730,000,000.00 | ROA | 17.58 % |
| Cashflow | Capital Expenditures | -76,273,000,000.00 | P/FCF | 31.74 |
| Cashflow | Free Cash Flow | 313,177,997,312.00 | – | – |
| Cashflow | Operating Cash Flow | 389,451,000,000.00 | P/CF | 25.52 |
| Income | Earnings per Share (diluted) | 263.72 | Div. Yield | 4.50 % |
| Income | Net Income | 434,012,000,000.00 | P/E | 22.90 |
| Income | Shares Outstanding | 1,645,730,000.00 | P/B | 4.91 |
| Income | Total Revenue | 1,246,078,000,000.00 | P/S | 7.90 |
Ratios calculated on: 10/14/2026
Company Description
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as well as the provision of literature research services for pharmaceutical information. The Overseas segment is engaged in the sale of its pharmaceutical products in oversea markets, such as Germany, the United Kingdom, France, Taiwan, China Mainland, Korea and the United States. This segment is also involved in the provision of pharmaceutical academic information, as well as the research, development and registration of pharmaceutical products. As of December 31, 2013, the Company had 20 subsidiaries.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.chugai-pharm.co.jp
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more